Johnson & Johnson (JNJ) FCF Margin (2009 - 2026)
Johnson & Johnson recorded quarterly FCF Margin of 6.09% in Q1 2026, down 72.67% quarter-over-quarter from 22.28% in Q4 2025, and down 935.0% year-over-year from 0.73% in Q1 2025.
Johnson & Johnson's FCF Margin history runs 18 years deep, the most recent figure standing at 6.09% for Q1 2026.
- In Q1 2026, FCF Margin fell 935.0% year-over-year to 6.09%; the TTM figure through Mar 2026 stood at 18.46% (down 435.0% YoY), while the FY2025 annual figure was 20.91%, down 143.0% from the prior year.
- FCF Margin came in at 6.09% for Q1 2026 at Johnson & Johnson, down from 22.28% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 33.39% in Q3 2025 to a low of 6.09% in Q1 2026.
- A 5-year average of 19.29% and a median of 17.0% in 2022 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin surged 2058 bps in 2023 and plunged 935 bps in 2026, its largest moves.
- Johnson & Johnson's FCF Margin stood at 17.0% in 2022, then soared by 73 bps to 29.32% in 2023, then retreated by 19 bps to 23.85% in 2024, then dropped by 7 bps to 22.28% in 2025, then sank by 73 bps to 6.09% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 6.09%, 22.28%, and 33.39% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 15.19% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 6.09% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 23.76% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 17.97% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 17.14% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 34.87% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 93.16% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 6.59% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 6.09% |
| Dec 28, 2025 | 22.28% |
| Sep 28, 2025 | 33.39% |
| Jun 29, 2025 | 11.94% |
| Mar 30, 2025 | 15.43% |
| Dec 29, 2024 | 23.85% |
| Sep 29, 2024 | 30.99% |
| Jun 30, 2024 | 20.75% |
| Mar 31, 2024 | 13.33% |
| Dec 31, 2023 | 29.32% |
| Oct 1, 2023 | 30.55% |
| Jul 2, 2023 | 14.21% |
| Apr 2, 2023 | 11.46% |
| Jan 1, 2023 | 8.75% |
| Apr 3, 2022 | 17.00% |
| Oct 3, 2021 | 32.32% |
| Jul 4, 2021 | 19.31% |
| Apr 4, 2021 | 15.22% |
| Jan 3, 2021 | 31.23% |
| Sep 27, 2020 | 36.27% |
| Jun 28, 2020 | 15.22% |
| Mar 29, 2020 | 13.21% |
| Dec 29, 2019 | 24.77% |
| Sep 29, 2019 | 32.72% |
| Jun 30, 2019 | 24.86% |
| Mar 31, 2019 | 14.42% |
| Dec 30, 2018 | 24.15% |
| Sep 30, 2018 | 26.80% |
| Jul 1, 2018 | 24.98% |
| Apr 1, 2018 | 14.73% |
| Dec 31, 2017 | 24.09% |
| Oct 1, 2017 | 27.87% |
| Jul 2, 2017 | 26.98% |
| Apr 2, 2017 | 13.24% |
| Jan 1, 2017 | 17.42% |
| Apr 3, 2016 | 8.87% |
| Sep 27, 2015 | 31.29% |
| Jun 28, 2015 | 26.46% |
| Mar 29, 2015 | 13.41% |
| Dec 28, 2014 | 17.03% |
| Sep 28, 2014 | 21.13% |
| Jun 29, 2014 | 24.07% |
| Mar 30, 2014 | 18.18% |
| Dec 29, 2013 | 14.76% |
| Sep 29, 2013 | 29.23% |
| Jun 30, 2013 | 23.94% |
| Mar 31, 2013 | 9.66% |
| Dec 30, 2012 | 12.67% |
| Sep 30, 2012 | 25.21% |
| Jul 1, 2012 | 22.14% |
| Apr 1, 2012 | 14.21% |
| Jan 1, 2012 | 1.65% |
| Apr 3, 2011 | 11.62% |
| Oct 3, 2010 | 30.08% |
| Jul 4, 2010 | 21.77% |
| Apr 4, 2010 | 21.07% |
| Jan 3, 2010 | 26.84% |
| Sep 27, 2009 | 30.34% |
| Jun 28, 2009 | 18.35% |
| Mar 29, 2009 | 15.92% |